02:22 , Apr 5, 2019 |  BC Innovations  |  Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
07:00 , Jun 2, 2016 |  BC Innovations  |  Translation in Brief

Setting boundaries

  The Stanford University laboratory that first showed exogenous shRNA can cause liver damage by overloading the microRNA machinery has found the molecular culprit behind the toxicity, and proposed quantitative guidelines for safer shRNA therapeutics....
07:00 , Aug 19, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) BRF2, subunit of RNA polymerase III transcription initiation factor, BRF1-like (BRF2) A study in cell culture and in patient...
07:00 , May 8, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Solid tumors RNA polymerase III (pol III); Brf1, a subunit of pol III transcription initiation factor IIIB A study in cell...
07:00 , Jun 7, 2004 |  BC Week In Review  |  Company News

Nucleonics, University of California deal

Nucleonics acquired an exclusive license from the university to IP covering a class of eukaryotic RNA polymerase III promoters for transcribing expressed interefering RNAs. Nucleonics is developing RNAi-based therapeutics for viral and other diseases. Nucleonics...